Document Type

Article

Publication Date

6-2025

Identifier

DOI: 10.1111/cts.70262; PMCID: PMC12117883

Abstract

Glucagon-like peptide-1 agonists (GLP-1A) are increasingly prescribed to treat obesity and type 2 diabetes mellitus in children and adolescents. Emerging evidence suggesting neuropsychiatric effects presents an opportunity for pediatric psychopharmacology but requires careful consideration of potential adverse effects and risk of misuse. This perspective examines potential applications and cautions surrounding GLP-1As for pediatric mental health, particularly substance use, depression, and eating disorders, and advocates for research and clinical monitoring to ensure their safety and efficacy.

Journal Title

Clin Transl Sci

Volume

18

Issue

6

First Page

70262

Last Page

70262

MeSH Keywords

Humans; Child; Adolescent; Glucagon-Like Peptide 1; Diabetes Mellitus, Type 2; Psychopharmacology; Substance-Related Disorders; Glucagon-Like Peptide-1 Receptor Agonists; Pediatric Obesity; Feeding and Eating Disorders

PubMed ID

40434284

Keywords

Glucagon-Like Peptide 1; Diabetes Mellitus, Type 2; Psychopharmacology; Substance-Related Disorders; Glucagon-Like Peptide-1 Receptor Agonists; Pediatric Obesity; Feeding and Eating Disorders

Comments

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Publisher's Link: https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.70262

Included in

Pediatrics Commons

Share

COinS